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Perioperative ␤-Blockade Protocol Unproven
To the Editor: I first became aware of the recent paper published in this journal not by my reading of ANESTHESIOLOGY, but through National Public Radio's Web site and the American Society of Anesthesiologists E-Newsletter of October 6, 2010. The National Public Radio story began with the following sentence: "Patients at risk of a heart attack who are having surgery can cut their death risk 35% by simply taking a drug called a ␤-blocker."* I write from the perspective of an anesthesiologist in private practice. Over the past several years, the hospital with which I am affiliated has eagerly adopted protocols for perioperative care. All Surgical Care Improvement Project mandates have become required. Currently, reimbursement from our largest private payer is tied to the World Health Organization Surgical Safety Checklist-an instrument whose utility has been presented but has not been clearly validated for hospitals such as ours.
1
Despite such pressures from administration, physicians must insist that mandated protocols dictating pathways of perioperative care require unequivocal evidence demonstrating overall benefit to patients.
The article published by Wallace in this journal's October 2010 issue looks back at San Francisco Veterans Administration Medical Center patients who had inpatient or outpatient surgery from 1996 to 2008.
2 During that time, a protocol for perioperative ␤-blockade was instituted at the San Francisco Veterans Administration Medical Center by Dr. Wallace, the author of the analysis. The protocol was not universally followed; it was voluntary. The protocol was based largely on evidence from a trial that had enrolled 200 patients, authored by Mangano, Layug, Wallace, and Tateo in 1996. 3 The patients in the analysis were not studied based on their participation in the author's protocol. They were studied in groups defined by their receipt of "at least one dose of B-blocker medication after surgery, either as an in-patient or out-patient."
During the time of the analysis, 30-day mortality decreased, as did 1-yr mortality. Over the time of the analysis, ␤-blocker use increased. Through regression and propensity analysis, the author concludes that the addition of a single dose of ␤-blocker during the perioperative period was independently associated with a reduction in 30-day and 1-yr mortality.
However, patients having vascular surgery did not share this benefit at the 1-yr mark, which stands in contrast to the results of a small prospective, randomized trial that showed remarkable benefit for vascular patients (odds ratio for cardiac death or nonfatal myocardial infarction over 22 months with ␤-blockade of 0.16 vs. placebo).
During the period of the analysis, other investigators conducted three large prospective, randomized trials of perioperative ␤-blockade that enrolled a total of 9,768 patients. None of these three prospective, randomized, controlled trials found overall benefit (decreased mortality) of the investigated protocol. [5] [6] [7] One statement in the Wallace article requires particular scrutiny. Wallace states in his conclusion that "appropriate use of the PCRRT protocol is clearly associated with a reduction in 30-day and 1-yr mortality." The analysis associates the addition of a single dose of any ␤-blocker with benefit, not the Perioperative Cardiac Risk Reduction Therapy protocol with benefit; this protocol was not an arm of this analysis.
Wallace's analysis does deserve careful study; in particular, regarding the hazard of withdrawing ␤-blockers during the perioperative period. In addition, the article suggests that some ␤-blockers administered to patients at risk may be helpful, and that patients who should have been taking ␤-blockers for medical indications, outside of any perioperative considerations, may present for surgery.
However, it cannot be argued that this analysis provides evidence for benefit of a particular protocol for perioperative ␤-blockade, certainly not one eligible for mandated care. (Accepted for publication January 25, 2011.) In Reply: van Klei et al. in their letter to the editor asked questions about statistical techniques used in our publication, "Association of the Pattern of Use of Perioperative ␤-Blockade and Postoperative Mortality," 1 to which we respond. The logistic regression model described in table 5 of the article describes the overall regression model in the high-risk patient group based on Perioperative Cardiac Risk Reduction Therapy criteria, including presence of coronary artery disease, peripheral vascular disease, or two risk factors (diabetes, hypertension, age older than 60 yr, smoking, or hyperlipidemia). As described in the Methods section, all risk factors such as preexisting medical conditions (age, sex, presence of known coronary artery disease, presence of known vascular disease, diabetes, hypertension, smoking, hypercholesterolemia, class of operation, medication use, revised cardiac risk index) were included in the model. However, only those chronic health risk factors that were significant and predictive of increased mortality were reported in table 5. Age is included as a significant risk factor. At the request of van Klei et al., we offer an expansion of table 5 from our article, 1 including nonsignificant risk factors; see table 1 for this information.
We were asked to clarify our methods of propensity matching, and we are pleased to do so. We used the risk factors of the original logistic regression model, including all nonsignificant risk factors, to develop propensity scores to predict the outcome: pattern of perioperative ␤-blockade ϭ none. Members of the other three groups were matched to the none group. An exact matching strategy was used, based on 12-digit propensity scores and allowing for more than one match per patient in the none group. Differences in outcomes-based ␤-blocker use pattern were determined by logistic regression.
As we discussed in the Limitations section of our manuscript, and as van Klei et al. emphasize, changes in practice patterns over time may have affected outcomes in our study, including unmeasured factors such as use of clonidine, statins, aspirin, minimally invasive surgery, off-pump coronary artery bypass graft, accuracy of administrative records, and other practice pattern shifts. We have performed a sensitivity analysis that forces "time" (number of years since 1996) into the multivariable analysis as a proxy for change in practice patterns (which, of course, includes changes in perioperative ␤-blockade practices). Inclusion of "time" in this manner has no effect on the analysis of the beneficial effects of perioperative ␤-blockade addition or the deleterious ef- for 30-day analysis, chi-square 8.63, P ϭ 0.37, c statistic ϭ 0.709; for 1-yr analysis, chi-square ϭ 3.97, P value ϭ 0.86, c statistic ϭ 0.657. Of note, all patients in the study group were "high risk." Some known long-term cardiac risk factors (e.g., hypercholesterolemia, hypertension) appear to be protective in the initial model. This paradox is explained by the fact that, in a high-risk population, patients included because of two minor risk factors are at lower risk than patients included because of major active diseases such as PVD. Risk factors that were nonsignificant and/or paradoxical were excluded from the final model. Addition ϭ addition of ␤-blocker; Continuous ϭ continuous use of ␤-blocker; 95% CI ϭ 95% confidence interval; None ϭ no ␤Ϫblockers before, during, or after surgery; PVD ϭ peripheral vascular disease; Withdrawal ϭ withdrawal of ␤-blocker.
